60 Degrees Pharmaceuticals, Inc. (SXTP)

NASDAQ: SXTP · IEX Real-Time Price · USD
0.286
-0.002 (-0.52%)
May 23, 2024, 4:00 PM EDT - Market closed
-0.52%
Market Cap 3.47M
Revenue (ttm) 569,863
Net Income (ttm) -1.01M
Shares Out 12.14M
EPS (ttm) -1.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,138,467
Open 0.290
Previous Close 0.287
Day's Range 0.271 - 0.299
52-Week Range 0.201 - 8.650
Beta n/a
Analysts Buy
Price Target 2.40 (+740.34%)
Earnings Date May 15, 2024

About SXTP

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory virus... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 12, 2023
Employees 3
Stock Exchange NASDAQ
Ticker Symbol SXTP
Full Company Profile

Financial Performance

In 2023, SXTP's revenue was $253,573, a decrease of -50.40% compared to the previous year's $511,210. Losses were -$3.92 million, -36.54% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SXTP stock is "Buy." The 12-month stock price forecast is $2.4, which is an increase of 740.34% from the latest price.

Price Target
$2.4
(740.34% upside)
Analyst Consensus: Buy
Stock Forecasts

News

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.

4 days ago - GlobeNewsWire

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand. Gross profit increased from ($55.9 thousand) to $51.0 thousand.

8 days ago - GlobeNewsWire

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.

16 days ago - GlobeNewsWire

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Trial planning and execution to proceed as planned WASHINGTON, May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focus...

22 days ago - GlobeNewsWire

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.

7 weeks ago - GlobeNewsWire

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.

2 months ago - GlobeNewsWire

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals Tafenoquine's presumed mode of action against C.

3 months ago - GlobeNewsWire

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.

3 months ago - GlobeNewsWire

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

JERSEY CITY, N.J. , Jan. 31, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, ...

4 months ago - PRNewsWire

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medic...

4 months ago - GlobeNewsWire

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

JERSEY CITY, N.J. , Jan. 30, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, ...

4 months ago - PRNewsWire

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

60 Degrees Pharma announces a $2.4 mil public offering, with funds to be used for working capital, relaunching ARAKODA for malaria prevention, and research

4 months ago - GlobeNewsWire

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

Post-FDA meeting, 60 Degrees Pharma plans pivotal study of tafenoquine in hospitalized babesiosis patients, aiming to start in summer 2024. #biotech #SXTP

4 months ago - GlobeNewsWire

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

WASHINGTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infecti...

4 months ago - GlobeNewsWire

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

60 Degrees Pharma has received IRB approval for a Phase IIA study evaluating tafenoquine's efficacy in treating hospitalized babesiosis patients, while the

5 months ago - GlobeNewsWire

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

Type C meeting will be to discuss a proposed Phase II study of tafenoquine for treatment of babesiosis Transmitted by ticks, babesiosis is a life-threatening parasitic disease increasing in frequency ...

6 months ago - GlobeNewsWire

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

60 Degrees Pharma Presents Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting

7 months ago - GlobeNewsWire

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

FDA advice to Company suggested execution of ACLR8-LR, a placebo-controlled Phase IIB study of tafenoquine in COVID-19 patients, may not be feasible in the U.S. Company will therefore focus efforts on...

8 months ago - GlobeNewsWire

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

WASHINGTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced that ...

8 months ago - GlobeNewsWire

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

WASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP), a pharmaceutical company focused on developing new medicines for infectious dis...

9 months ago - GlobeNewsWire

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money R...

Other symbols: GENE
9 months ago - Accesswire

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

WASHINGTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced the j...

9 months ago - GlobeNewsWire

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

WASHINGTON, Aug. 22, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals (“60P”) (Nasdaq: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced that the Uni...

9 months ago - GlobeNewsWire

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

WASHINGTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (“60 Degrees Pharmaceuticals” or “60P”) (NASDAQ: SXTP), a company specializing in developing and marketing medicines for ...

10 months ago - GlobeNewsWire

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

WASHINGTON, July 31, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP), a pharmaceutical company focused on developing new medicines for infectious disea...

10 months ago - GlobeNewsWire